AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US$1.28 million contract is with an existing AtCor customer and will expand the use of SphygmoCor in a current trial.
Duncan Ross, CEO of AtCor Medical said, “We are very pleased to continue to expand our relationship with this important customer. Our strong deal flow in the pharma sector further reinforces AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients. Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as an independent predictor and critical measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice”.
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals.